| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $30,000,000 | 2 | 15 |
Sells | $505,080 | 11 | 85 |
| ORBIMED ADVISORS LLC | 1 | $15M | 0 | $0 | $15M | |
| Xu Diyong | 1 | $15M | 0 | $0 | $15M | |
| Violette Shelia M. | Chief Scientific Officer | 0 | $0 | 3 | $66,672 | $-66,672 |
| Kalowski Lee | CFO and President | 0 | $0 | 4 | $126,031 | $-126,031 |
| Morrison Jodie Pope | CEO | 0 | $0 | 4 | $312,377 | $-312,377 |
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal …
Over the last 12 months, insiders at Q32 Bio Inc. have bought $30M and sold $505,080 worth of Q32 Bio Inc. stock.
On average, over the past 5 years, insiders at Q32 Bio Inc. have bought $30M and sold $183,906 worth of stock each year.
Highest buying activity among insiders over the last 12 months: ORBIMED ADVISORS LLC () — $15M. Xu Diyong () — $15M.
The last purchase of 1,875,000 shares for transaction amount of $15M was made by Xu Diyong () on 2026‑05‑28.
| 2026-10-06 | Sale | Morrison Jodie Pope | CEO | 3,221 0.0111% | $8.32 | $26,798 | +6.47% | |
| 2026-10-06 | Sale | Kalowski Lee | CFO and President | 1,301 0.0045% | $8.32 | $10,824 | +6.47% | |
| 2026-10-06 | Sale | Violette Shelia M. | Chief Scientific Officer | 917 0.0032% | $8.32 | $7,629 | +6.47% | |
| 2026-08-25 | Sale | Morrison Jodie Pope | CEO | 9,845 0.0336% | $16.56 | $163,033 | -45.40% | |
| 2026-08-25 | Sale | Kalowski Lee | CFO and President | 3,972 0.0135% | $16.56 | $65,776 | -45.40% | |
| 2026-08-25 | Sale | Violette Shelia M. | Chief Scientific Officer | 2,798 0.0095% | $16.56 | $46,335 | -45.40% | |
| 2026-05-28 | Xu Diyong | 1.88M 11.3875% | $8.00 | $15M | +22.60% | |||
| 2026-05-28 | ORBIMED ADVISORS LLC | 1.88M 11.3875% | $8.00 | $15M | +22.60% | |||
| 2026-02-25 | Sale | Morrison Jodie Pope | CEO | 9,896 0.0768% | $4.51 | $44,675 | +89.96% | |
| 2026-02-25 | Sale | Violette Shelia M. | Chief Scientific Officer | 2,815 0.0218% | $4.51 | $12,708 | +89.96% | |
| 2026-02-25 | Sale | Kalowski Lee | CFO and President | 3,995 0.031% | $4.51 | $18,035 | +89.96% | |
| 2025-12-02 | Sale | Morrison Jodie Pope | CEO | 22,506 0.1889% | $3.46 | $77,871 | +109.38% | |
| 2025-12-02 | Sale | Kalowski Lee | CFO and President | 9,072 0.0762% | $3.46 | $31,395 | +109.38% | |
| 2025-08-26 | Sale | Morrison Jodie Pope | CEO | 10,494 0.0459% | $1.80 | $18,900 | +157.69% | |
| 2025-08-26 | Sale | Violette Shelia M. | Chief Scientific Officer | 2,990 0.0131% | $1.80 | $5,385 | +157.69% | |
| 2025-08-26 | Sale | Kalowski Lee | CFO and President | 4,240 0.0185% | $1.80 | $7,636 | +157.69% | |
| 2024-03-25 | Sale | TZIANABOS ARTHUR | director | 265 0.0156% | $24.20 | $6,413 | +53.48% | |
| 2024-03-25 | Sale | Alloway Paul | See Remarks | 268 0.0157% | $24.21 | $6,488 | +53.48% | |
| 2024-03-25 | Sale | Michaud Charles Jr | See Remarks | 75 0.0044% | $24.20 | $1,815 | +53.48% |
| Increased Positions | 16 | +22.54% | 478,795 | +5.87% |
| Decreased Positions | 28 | -39.44% | 863,714 | -10.6% |
| New Positions | 7 | New | 295,130 | New |
| Sold Out Positions | 8 | Sold Out | 161,069 | Sold Out |
| Total Postitions | 59 | -16.9% | 8M | -4.72% |